DexCom, Inc. $DXCM Shares Sold by Lyell Wealth Management LP

Lyell Wealth Management LP reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 14.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,836 shares of the medical device company's stock after selling 8,156 shares during the quarter. Lyell Wealth Management LP's holdings in DexCom were worth $4,088,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of DXCM. Nuveen LLC acquired a new stake in shares of DexCom in the first quarter valued at approximately $554,893,000. Jennison Associates LLC grew its position in shares of DexCom by 37.7% in the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock valued at $718,632,000 after purchasing an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of DexCom by 171.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after purchasing an additional 2,015,971 shares during the last quarter. Federated Hermes Inc. grew its position in shares of DexCom by 2,371.4% in the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company's stock valued at $136,220,000 after purchasing an additional 1,914,019 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company's stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares of the company's stock, valued at $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,849 shares of company stock worth $564,733. Company insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of DXCM opened at $66.60 on Monday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $26.12 billion, a price-to-earnings ratio of 46.25, a PEG ratio of 1.40 and a beta of 1.47. The company's 50 day simple moving average is $73.35 and its 200 day simple moving average is $77.69. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue was up 15.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently commented on DXCM shares. UBS Group increased their price target on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Weiss Ratings reiterated a "hold (c-)" rating on shares of DexCom in a research report on Wednesday, October 8th. Truist Financial lowered their price target on shares of DexCom from $102.00 to $94.00 and set a "buy" rating on the stock in a research report on Wednesday, October 15th. Citigroup reduced their price objective on shares of DexCom from $105.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, October 7th. Finally, Raymond James Financial upped their price objective on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $97.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.